ANGLE PLC (AIM: AGL, OTCQX: ANPCY) has revealed new research indicating that analysing entire tumour cells in the bloodstream, rather than solely DNA fragments, may offer a more comprehensive understanding
Angle PLC (AIM:AGL OTCQX:ANPCY) Study of ovarian cancer CTCs using Parsortix
ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a leader in liquid biopsy technology, has reported encouraging results from a study using its Parsortix system to predict progression-free survival among ovarian cancer
Angle PLC ( AIM:AGL OTCQX:ANPCY) Breakthrough clinical results
ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a specialist in liquid biopsy, announced a significant advancement in cancer diagnostics, offering more personalized and actionable insights into the disease and its progression.
Angle PLC (AGL.L) Update on submission for FDA clearance
Response to Additional Information Request made to FDA as planned
Angle PLC (AGL.L) Research confirms high performance of Parsortix
PARSORTIX SYSTEM IS “IDEAL CTC PLATFORM FOR USE IN CLINICAL TRIALS AND CLINICAL PATIENT MANAGEMENT”